Pennsylvania 2025-2026 Regular Session

Pennsylvania Senate Bill SB865

Introduced
6/18/25  

Caption

In miscellaneous provisions, further providing for urine drug screening requirement and providing for medetomidine awareness education.

Impact

The implications of SB865 extend into state laws concerning drug testing and medical education. If enacted, it would require healthcare facilities to comply with standardized urine drug screening protocols and initiate awareness programs focused on medetomidine. This change could potentially improve patient safety and clinical outcomes by ensuring that both patients and medical professionals are well-informed about the risks and proper handling of medetomidine.

Summary

SB865 proposes to implement specific requirements for urine drug screening and enhance educational efforts regarding medetomidine awareness. The bill seeks to standardize procedures around drug screening to ensure consistency and effectiveness across various healthcare settings. By addressing these facets, SB865 emphasizes the importance of monitoring and education concerning medetomidine, an anesthetic agent that has raised safety concerns in clinical use.

Sentiment

Overall sentiment surrounding SB865 appears to be favorable among healthcare professionals, who recognize the need for improved drug screening and education as critical elements in enhancing patient safety. Stakeholders argue that effective implementation of urine drug screening is necessary for identifying substance misuse early, while educational initiatives regarding medetomidine are essential to mitigate potential risks associated with its administration.

Contention

Despite the general support, there may be points of contention regarding the costs and logistics of implementing the standardized drug screening and educational programs. Some critics could raise concerns about whether the new requirements might place an undue burden on smaller healthcare facilities and how effectively these initiatives will be monitored and enforced. Additionally, discussions may arise about the adequacy of resources provided for education and training on medetomidine.

Companion Bills

No companion bills found.

Previously Filed As

PA HB1212

In miscellaneous provisions, providing for drug screening and awareness education and for fatherhood engagement in maternal health; and imposing duties on the Joint State Government Commission.

PA SB866

Further providing for schedules of controlled substances and for secure storage of xylazine; and adding provisions relating to medetomidine.

PA A1816

Requires hospitals to test for fentanyl and xylazine as part of urine drug screenings.

PA SB732

In preliminary provisions, further providing for definitions; in patients, further providing for prohibitions; in miscellaneous provisions, further providing for protections for patients and caregivers and providing for enforcement and civil actions; and promulgating regulations.

PA A3680

Requires hospital urine drug screenings to include test for fentanyl.

PA S800

Requires hospital urine drug screenings to include test for fentanyl.

PA HB77

In food protection, further providing for definitions, providing for food allergy awareness and further providing for powers of department.

PA HB662

In preliminary provisions, further providing for definitions; and, in miscellaneous, providing for release testing and reimbursement.

PA SB523

In miscellaneous provisions relating to emergency management services, providing for health screenings for firefighters and EMS providers.

PA HB1304

In administration and miscellaneous provisions, further providing for stress test of system; and, in administration, funds, accounts and general provisions, further providing for stress test of system.

Similar Bills

MD HB1109

Public Health Reform Act

MD HB417

Criminal Law - Schedule III Controlled Dangerous Substances - Medetomidine and Xylazine

MD SB435

Public Health - Medetomidine and Xylazine Consumer Protection Act

SD HB1169

Classify medetomidine as a Schedule III controlled substance and establish permissible uses.

MD SB875

Public Health – Medetomidine and Xylazine Consumer Protection Act

PA SB866

Further providing for schedules of controlled substances and for secure storage of xylazine; and adding provisions relating to medetomidine.

NY S09221

Directs the commissioner of the office of alcoholism and substance abuse services to establish a program for individuals to receive free drug test strips to detect the presence of medetomidine, benzodiazepine, nitazenes, and/or other harmful contaminants; directs the commissioner of the office of alcoholism and substance abuse services, in cooperation with the commissioner of the department of health, to develop and conduct a public awareness and educational campaign on the dangers of medetomidine, benzodiazepine, nitazenes, and/or other harmful contaminants.

NY A09001

Directs the commissioner of the office of alcoholism and substance abuse services to establish a program for individuals to receive free drug test strips to detect the presence of medetomidine, benzodiazepine, nitazenes, and/or other harmful contaminants; directs the commissioner of the office of alcoholism and substance abuse services, in cooperation with the commissioner of the department of health, to develop and conduct a public awareness and educational campaign on the dangers of medetomidine, benzodiazepine, nitazenes, and/or other harmful contaminants.